bioAffinity reports 235 CyPath Lung tests in October 2026, up 29% year over year
No financial results were reported, so there is no beat, miss, or in-line comparison with the supplied FY2026 guidance. bioAffinity reported 235 CyPath Lung tests performed in October 2026, up 29% from October 2025, and said the volume was the highest monthly level for the test. October volume was approximately 45% of all tests performed in Q3 2026.
Key takeaways
Testing volume: bioAffinity reported 235 CyPath Lung tests performed in October 2026, the highest monthly testing volume disclosed for the test.
Year-over-year growth: October 2026 testing volume increased 29% compared with October 2025.
Quarterly contribution: October 2026 testing volume represented approximately 45% of all tests performed in Q3 2026.
Physician utilization: The company reported continued growth in testing by established and newly ordering physicians.
Commercial expansion: The company said it expanded its sales team and is pursuing direct physician engagement, distribution relationships, and opportunities within government healthcare systems.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow BIAF in real time
Get material earnings, filing, IR, and earnings-call alerts by email.